Table 2.

Serum aminotransferase and lipids at baseline and euthanasia

PHASE	GROUP	AST	ALT	CHOL	HDL	TGC
Baseline	Placebo	52.8±14.8	85.9±29.7	31.9±16.2	22.4±11.0	49.5±16.3
	Ramipril	51.2±18.1	68.7±29.2	38.4±28.0	22.5±9.2	45.7±19.4
	Control	70.0±43.7	92.2±47.8	18.4±10.7	14.7±6.6	70.7±34.6
p-value*		0.463	0.332	0.107	0.128	0.099
Euthanasia	Placebo	86.1±32.8a	98.5±47.9a	970.7±156.6a	306.2±72.1a	384.9±307.7a
	Ramipril	86.5±39.6a	104.3±54.1a	989.3±102.7a	234.2±80.6a,b	282.7±175.6a
	Control	50.6±23.0	92.7±37.7	18.1±6.19	13.0±6.2	76.2±48.6
p-value*		0.019	0.876	< 0.001	< 0.001	0.001
Baseline x Euthanasia	Placebo	0.023 (d=0.87)	0.383 (d=0.29)	< 0.001 (d=6.29)	< 0.001 (d=4.06)	0.007 (d=1.09)
p-value (Cohen’s d)**	Ramipril	0.027 (d=0.84)	0.120 (d=0.54)	< 0.001 (d=10.3)	< 0.001 (d=2.67)	0.002 (d=1.34)
	Control	0.218 (d=0.45)	0.976 (d=0.01)	0.919 (d=0.03)	0.479 (d=0.25)	0.769 (d=0.10)

Data represent means ± standard deviations. AST, aspartate aminotransferase (U/L); ALT, alanine aminotransferase (U/L); CHOL, total cholesterol (mg/dl); HDL, high-density lipoprotein cholesterol (mg/dl); TGC, triglyceride (mg/dl).

^*Oneway ANOVA and LSD post hoc test;

^**Paired Student’s t test.

^aSignificant difference compared to control group (AST): placebo (P=0.013, r=0.55), ramipril (P=0.013, r=0.50); CHOL: placebo (P < 0.001, r=0.98), ramipril (P < 0.001, r=0.99); HDL: placebo (P < 0.001, r=0.95), ramipril (P < 0.001, r=0.89); TGC: placebo (P=0.004, r=0.58), ramipril (P=0.042, r=0.64).

^bSignificant difference compared to placebo group (HDL): P=0.018, r=0.44.